Evolocumab - Lipid modification
You are here : Home > Formulary Search > Evolocumab - Lipid modification
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Red
Formulations :
- Subcutaneous injection (sc)
Formulary Status :
Associated Icons :
Restrictions / Comments :
Documentation
NICE Technology Appraisal
Evidence Review
PAD Profile
ChemicalSubstance :
Evolocumab
Indication :
Lipid modification
Group Name :
Keywords :
Dyslipidaemia, hyperlipidaemia, lipid modification, high cholesterol, raised cholesterol, Lipid regulating, PCSK9 Inhibitor, heterozygous familial hypercholesterolaemia, non-familial hypercholesterolaemia
Brand Names Include :
Repatha
Important Information :
Restricted to lipidologists only for heterozygous familial and non-familial hypercholesterolaemia.
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
5
Other Indications
Below are listed other indications that Evolocumab is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Lipid modification.
Committee Recommendations (1)
The PCN recommends evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia in line with NICE TA394 (June 2016)
Prescribing will be initiated and treatment continued by specialists with training in lipid management and notification of initiation and continuation of treatment will be via the Blueteq database. Evolocumab will be considered RED on the traffic light system
Prescribing will be initiated and treatment continued by specialists with training in lipid management and notification of initiation and continuation of treatment will be via the Blueteq database. Evolocumab will be considered RED on the traffic light system